Latest On Capricor Therapeutics, Inc (CAPR):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-12 07:12 EST | News | Capricor Therapeutics, Inc. (CAPR) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-11 17:36 EST | News | Capricor Therapeutics GAAP EPS of -$0.31 beats by $0.01, revenue of $2.98M beats by $2.48M | N/A | |
| 2023-03-16 00:26 EST | News | Capricor Therapeutics GAAP EPS of -$0.31 beats by $0.03, revenue of $0.96M beats by $0.96M | N/A | |
| 2023-03-16 00:26 EST | News | Capricor Therapeutics, Inc. (CAPR) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-14 18:00 EST | News | Capricor Therapeutics Q4 2022 Earnings Preview | N/A | |
About Capricor Therapeutics, Inc (CAPR):
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. Capricor collaborates wi read more...th Lonza for the development of CAP-1002, its cell therapy candidate for the treatment of Duchenne muscular dystrophy and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.
General
- Name Capricor Therapeutics, Inc
- Symbol CAPR
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Last Split Factor1:10
- Last Split Date2019-06-05
- Fiscal Year EndDecember
- IPO Date2007-02-13
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.capricor.com
Valuation
- Price/Sales (Trailing 12 Mt.) 149.52
- Price/Book (Most Recent Quarter) 4.13
- Enterprise Value Revenue 190.86
- Enterprise Value EBITDA 0.03
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.00
- Next Year EPS Estimate -$1.06
- Operating Margin -4413%
- Return on Assets -37%
- Return on Equity -78%
- Revenue 310250
- Earnings Per Share -$3.74
- Revenue Per Share $0.02
- Gross Profit -8146750
- Quarterly Earnings Growth -74%
Highlights
- Market Capitalization 118.78 million
- EBITDA -11929662
- Analyst Target Price $12
- Book Value Per Share $1.37
Share Statistics
- Shares Outstanding 22.8 million
- Shares Float 19.99 million
- % Held by Insiders 253%
- % Held by Institutions 6.2%
- Shares Short 345150
- Shares Short Prior Month 489136
- Short Ratio 0.36
- Short % of Float 2%
- Short % of Shares Outstanding 2%
Technicals
- Beta 6.47
- 52 Week High $12.32
- 52 Week Low $0.96
- 50 Day Moving Average 6.37
- 200 Day Moving Average 5.05
Dividends
- Dividend Date 2019-06-05
- ExDividend Date N/A
- Dividend Yield 0%
Capricor Therapeutics, Inc (CAPR) Dividend Calendar:
CAPR's last dividend payment was made to shareholders on June 5, 2019.
Capricor Therapeutics, Inc (CAPR) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Capricor Therapeutics, Inc (CAPR) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Capricor Therapeutics, Inc (CAPR) Chart:
Capricor Therapeutics, Inc (CAPR) News:
Below you will find a list of latest news for Capricor Therapeutics, Inc (CAPR) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Capricor Therapeutics, Inc (CAPR) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest CAPR Trades:
Capricor Therapeutics, Inc (CAPR) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-09-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-25 | 8-K (Current report) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-07-29 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-17 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-06-17 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-06-09 | 8-K (Current report) | |
| 2020-06-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-28 | 8-K (Current report) | |
| 2020-05-19 | 424B3 (Prospectus [Rule 424(b)(3)]) | |
| 2020-05-19 | EFFECT (Notice of Effectiveness) | |
| 2020-05-15 | 8-K (Current report) | |
Capricor Therapeutics, Inc (CAPR) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Capricor Therapeutics, Inc (CAPR). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 253%
Institutional Ownership: 620%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-24 | Louis Manzo | Director | Buy | 8,299.00 | 3.70 | 30,706.30 | 44,603.00 | |
| 2020-07-27 | Linda Marban | CHIEF EXECUTIVE OFFICER | Buy | 41,497.00 | 3.70 | 153,538.90 | 62,367.00 | |
| 2019-12-17 | Frank Litvack | Director | Buy | 20,391.00 | 20,391.00 | | ||
| 2019-12-17 | David B Musket | Director | Buy | 20,391.00 | 22,891.00 | | ||
| 2019-12-17 | Louis Manzo | Director | Buy | 20,391.00 | 36,304.00 | | ||
| 2017-12-22 | Rachel Smith | Vice President of R&D | Buy | 20,748.00 | 0.16 | 3,319.68 | 20,748.00 | |
| 2017-10-23 | Louis Manzo | Director | Buy | 20,748.00 | 0.16 | 3,319.68 | 159,132.00 | |